Cambridge biopharmaceutical company Acceleron Pharma Inc. has just registered for an initial public offering of stock that could raise up to $74.8 million.
The number of shares to be offered and the price range for the offering have not been determined, the company said.
Through late July, five Massachusetts biotechnology start-ups had gone public so far this year. And Foundation Medicine of Cambridge, a supplier of genomic testing for cancer patients, recently filed plans with regulators to raise $86.25 million by going public.
In March, Acceleron said that the Food and Drug Administration had granted orphan drug designation for its ACE-536 drug candidate as a potential treatment for two rare blood disorders.
In its regulatory filing Acceleron said it is focused on the discovery, development, and commercialization therapeutics for cancer and rare diseases.
The company also said in the filing that it lost nearly $32.6 million on revenues of about $15.3 million in 2012.
Citigroup and Leerink Swann LLC will act as joint book-running managers for the offering. Piper Jaffray & Co. will act as lead manager and JMP Securities will act as co-manager for the offering, Acceleron said.